# EDGAR Filing Document

**Accession Number:** 0000944809
**File Stem:** 0000944809-23-000002
**Filing Date:** 2023-1
**Character Count:** 5174
**Document Hash:** cd1b461caff4ed6bc2d3cfc96f612c3e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000944809-23-000002.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0000944809-23-000002

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230103

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OPKO HEALTH, INC.
- **CENTRAL INDEX KEY:** 0000944809
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 752402409
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33528
- **FILM NUMBER:** 23502293

**BUSINESS ADDRESS:**
- **STREET 1:** 4400 BISCAYNE BLVD.
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33137
- **BUSINESS PHONE:** 305-575-4181

**MAIL ADDRESS:**
- **STREET 1:** 4400 BISCAYNE BLVD.
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33137

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Opko Health, Inc.
- **DATE OF NAME CHANGE:** 20070621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** eXegenics Inc
- **DATE OF NAME CHANGE:** 20040505

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EXEGENICS INC
- **DATE OF NAME CHANGE:** 20011114

?xml version="1.0" ? opk-20230103

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 3, 2023

**OPKO Health, Inc.** 

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-33528** | **75-2402409** |
| (State or Other Jurisdiction <br>of Incorporation) | (Commission <br>File Number) | (IRS Employer <br>Identification No.) |

---

---

| | | | |
|:---|:---|:---|:---|
| **4400 Biscayne Blvd.** | **Miami,** | **Florida** | **33137** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: (305) 575-4100

---

| |
|:---|
| **Not Applicable** |
| Former name or former address, if changed since last report |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | OPK | NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;☐&nbsp;&nbsp;&nbsp;&nbsp;

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☐

------

---

| | |
|:---|:---|
| **ITEM 8.01.** | **Other Events.** |

---

On January 3, 2023, OPKO Health, Inc. ("<u>OPKO</u>" or the "<u>Company</u>") provided notice to holders of the 3.00% Convertible Senior Notes due 2033 (the "Notes") of their repurchase right pursuant to the terms of Section 3.3(c) of the Indenture, dated January 30, 2013, between OPKO and Wells Fargo Bank, National Association (the "Notice"), as filed with the Securities and Exchange Commission on February 5, 2013 on the Company's Current Report on Form 8-K. Each holder of Notes can require that OPKO purchase for cash, all or a portion of such holder's Notes, for 100% of the principal amount of the Notes being tendered for repurchase, plus accrued and unpaid interest thereon. As of today's date, approximately $3.0 million aggregate principal amount of the Notes remain outstanding. Pursuant to the Notice, the last date on which a holder may exercise their repurchase right is January 31, 2023.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | OPKO Health, Inc. | OPKO Health, Inc. |
| | By: | /s/ Adam Logal |
| Date: January 3, 2023 | Name: | Adam Logal |
|  | Title: | Senior Vice President, Chief Financial Officer |

---